



UPDATE OF STOPP/START CRITERIA IN 2023: WHAT ARE THE IMPACTS ON OUR PHARMACEUTICAL INTERVENTIONS?

Verchin Marine¹, Fillatre Adrien², Dupont Amélie², Cottrez Kevin², Mahboub Yanis²

¹ Saint-Quentin Hospital, Geriatric Unity, Saint-Quentin, France.


² Saint-Quentin Hospital, Pharmacy, Saint-Quentin, France.



Background

Since their first versions, the **STOPP/START criteria** have demonstrated their interest in clinical pharmacy practices.

In 2023, these criteria were updated in line with advances in clinical research.
This new version requires us to update our knowledge and practices.



Objective

Assess the impact of the **3rd version of the STOPP/START criteria** on our pharmaceutical interventions (PI) in both geriatric and non-geriatric services.



Method

Prospective analysis of **75 prescriptions**

50 from geriatric services (acute care and nursing homes)

25 from non-geriatric medical services with patients over 65 years old

The **number of PIs** concerning the common to versions 2 and 3 was recorded and the number of PIs related to the new criteria in 2023 (version 3).

Results



Average age : 84.2 years for non-geriatric and 83.7 years for geriatric services

Number of prescriptions : 11.5 vs 12.2 lines

84% and 72% respectively contain at least one inappropriate medication.

New criteria in version 3 represented 31 PIs, 10 and 21 PIs, respectively, representing **0.16 and 0.42 criteria per patient**.

Benzodiazepines for anxiety for ≥ 4 weeks was the most commonly criteria (8 patients). **Benzodiazepines for insomnia for ≥ 2 weeks** was the most commonly version 3 criteria (13 patients).

Conclusion

The third version of the STOPP/START criteria impacts our clinical pharmacy practices, leading to an **increase in the number of PIs** in prescriptions analyzed within our institution, **across all sectors**. This new version will affect the medication management of these polypharmacy elderly patients.

